^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    DecisionDx® DiffDx-Melanoma

    Company:
    Castle Biosci
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    DecisionDx® DiffDx™-Melanoma is a new gene expression profile test designed to reduce diagnostic uncertainty by providing a highly accurate and objective evaluation. DiffDx-Melanoma adds diagnostic clarity leading to a more confident diagnosis and a clearer treatment path for patients.
    Cancer:
    Melanoma
    Gene:
    BAP1 (BRCA1 Associated Protein 1), BCL2A1 (BCL2 Related Protein A1), DCT (Dopachrome Tautomerase), DUSP4 (Dual Specificity Phosphatase 4), GATA3 (GATA binding protein 3), GJA1 (Gap Junction Protein Alpha 1)
    See More ...